Minoxidil Use linked to Infant Hair Growth & Eye Disorders in global Safety Analysis
Table of Contents
A comprehensive global safety analysis has revealed a concerning link between minoxidil, a popular over-the-counter hair loss treatment, adn unintended exposure in infants, resulting in reports of excessive hair growth and a meaningful number of eye-related side effects. The analysis, covering data up to March 2025, flagged dozens of cases involving babies and over 1,600 reports of eye disorders worldwide.
The study, based on adverse drug reports submitted to VigiBase – the World Health Institution’s (WHO) global drug safety database – raises critical questions about the accessibility and awareness surrounding the drug’s potential risks.
Unintentional Infant Exposure a Growing Concern
Researchers identified more than 45 reports of excessive hair growth in infants up to 23 months old linked to minoxidil exposure.Alarmingly, a ample portion of these cases – 44.4% – were attributed to accidental exposure, not direct request. This included contact with caregivers or contaminated household surfaces.
Globally, the analysis documented 2,664 suspected cases of excessive hair growth connected to minoxidil use during pregnancy. Maternal exposure accounted for 22.2% of infant cases, while the route of exposure remained unclear in roughly one-third (33.3%) of instances.
While no infant cases were reported specifically from India,the study authors cautioned that this likely reflects under-reporting,given the drug’s widespread availability and use within the country. “The absence of reported cases from India should not be interpreted as an absence of risk,” one researcher stated.
Eye Health Risks Highlighted in New Data
Beyond infant exposure, the analysis also revealed a significant number of adverse eye effects associated with minoxidil use. A total of 1,660 reports of eye-related problems were recorded globally, including 25 from India. Common complaints included eyelid swelling and blurred vision.
More serious conditions were also noted, including central serous chorioretinopathy, a rare eye disease. After removing duplicate reports,four serious eye cases remained – three involving central serous chorioretinopathy and one case of retinal artery occlusion.
From Blood Pressure medication to Hair Loss Cure
Originally developed as an oral medication for high blood pressure,minoxidil‘s hair growth side effect led to its reformulation as a topical treatment for androgenetic alopecia,commonly known as pattern baldness.It has sence become one of the most frequently used hair loss treatments worldwide.
The study’s authors attribute the rising concerns to the drug’s easy over-the-counter availability, aggressive online promotion, and a lack of comprehensive counseling for potential users. They emphasized that minoxidil is contraindicated during pregnancy and breastfeeding, yet awareness of this warning remains surprisingly low.
Calls for Increased Safety Measures
The researchers are urging for immediate action to mitigate the risks associated with minoxidil use. Recommendations include clearer warning labels, stricter oversight of over-the-counter sales, and routine counseling by pharmacists and healthcare providers.
Caregivers are strongly advised to store minoxidil products safely and avoid their use around infants and pregnant women. “Unintentional exposure through skin contact or household surfaces may place infants at risk,” the study warns.
the authors of the study, Dr. V Kalaselvan and Dr. jaishree suresh of the Indian pharmacopoeia Commission, health ministry, and Dr. Rohit Saxena of the Dr. Rajendra Prasad Center for Ophthalmic Sciences, AIMS, stressed that while minoxidil continues to benefit adults seeking treatment for hair loss, public awareness and robust pharmacovigilance must evolve alongside its increasing use to prevent avoidable adverse effects.
